Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT03565367
A Pilot Study to Assess Lactate and Bicarbonate Detection Within Malignant Brain Tumors Using [1-13C]-Pyruvate DNP Magnetic Resonance Spectroscopy (MRS)
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Inclusion Criteria:
- Patients with a known diagnosis of central nervous system (CNS) malignancy, including
metastases, with known enhancement on magnetic resonance (MR) who are otherwise
eligible to undergo MRI
- Glomerular filtration rate (GFR) > 30 ml/min
- No allergy to gadolinium
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Refusal to have an IV placed for injection
- Acute major illness (e.g., unstable angina, etc.) or other condition that makes
participation unsafe, per the investigator?s judgement
- Total bilirubin > 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
- Gamma-glutamyltransferase (GGT) > 2.5 x ULN
- Pregnant or breast-feeding
- Cardiovascular risk, including:
- Poorly controlled hypertension, defined as either systolic > 170 or diastolic >
110
- Congestive heart failure
- Myocardial infarction within the past year
- QT prolongation, defined as pretreatment corrected QT interval (QTc) > 440 msec
in males or > 460 msec in females
other: Gadolinium
drug: Hyperpolarized Carbon C 13 Pyruvate
procedure: Magnetic Resonance Imaging
procedure: Magnetic Resonance Spectroscopic Imaging
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Lewis Naya
650-725-0739